Several anti-VEGF drugs including bevacizumab, ranibizumab, pegaptanib, and aflibercept have been investigated in the context of ROP, but only ranibizumab has received the indication for the treatment of ROP in Europe and Japan (Lee and Shirley, 2021). This evidence concerns the gene VEGFA and retinopathy of prematurity.